Filing Flows › Industrials › iSpecimen (ISPC)
iSpecimen (ISPC) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · iSpecimen (ISPC) Q2 2026 earnings results →
Q2 2026 Revenue down 79% year over year to $152K · 897¢ of every $1 of revenue lost · operating margin -897.1%
iSpecimen made $152K in Q2 2026 (-79% Y/Y): Product $125K, Shipping and Handling $27K. Operating margin -897.1%, net loss $1.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $152K in Q2 2026, down 79% year over year and down 3% from the previous quarter. Product was the largest line at 83% of revenue. Product lost $546K year over year (down 81%), 97% of the total change.
Operating costs exceeded revenue by $1.4M, an operating margin of -897.1%. Total costs fell 40% while revenue fell 79%. The fastest-growing cost line was Sales & marketing (+111%). The quarter ended with a net loss of $1.4M, narrower than the previous quarter's $2.3M loss.
Operating cash flow was −$690K. Non-cash charges added back $201K of depreciation and amortization and $0K of share-based compensation. Working capital and other items added $472K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $152K | -79% | -897.1% | −$1.4M | −$690K |
| Q1 2026 | 10-Q | May 18, 2026 | $156K | -85% | n/m | −$2.3M | −$3.4M |
| Q4 2025 | 10-K | Apr 1, 2026 | $52K | -96% | n/m | −$5.0M | −$917K |
| Q3 2025 | 10-Q | Nov 17, 2025 | $107K | -96% | n/m | −$2.8M | −$2.0M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $713K | -75% | -255.4% | −$1.0M | −$192K |
| Q1 2025 | 10-Q | May 19, 2025 | $1.1M | -54% | -154.9% | −$1.7M | −$1.1M |
| Q4 2024 | 10-K | Apr 14, 2025 | $1.5M | -43% | -395.8% | −$6.0M | −$3.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About iSpecimen
iSpecimen’s mission is to accelerate life science research, discovery and development with a global marketplace platform that connects researchers to subjects, specimens, and associated data. Our vision is to create an “Amazon-like” global Marketplace of patients, biospecimens, and data for research to improve the quality of human life. We implement employee programs that foster a company culture predicated on the core values of corporate and individual growth, results and accountability, team before self; a can-do positive attitude, and the perseverance to succeed.
In its own words, from its 10-K, filed Apr 1, 2026.
iSpecimen against its Services-Commercial Physical & Biological Research peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -79% against the peers' median +8%. Operating margin: -897.1% against the peers' median 12.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ISPC iSpecimen | Q2 2026 | $152K | -79% | -897.1% |
| IQV IQVIA Holdings | Q3 2026 | $4.4B | +8% | 12.9% |
| INCY Incyte | Q3 2026 | $1.6B | +14% | -45.5% |
| CRL Charles River Laboratories International | Q3 2026 | $983M | -2% | 20.6% |
| MEDP Medpace Holdings | Q3 2026 | $716M | +8% | 23.1% |
| NRC NRC Health | Q3 2026 | $38.4M | +11% | 23.2% |
| MXCT Maxcyte | Q2 2026 | $7.3M | -14% | -140.7% |
| FOXO Foxo Technologies | Q2 2026 | $4.7M | -10% | 185.5% |
| OABI OmniAb | Q3 2026 | $4.0M | +78% | -409.9% |
Source: iSpecimen 10-Q on SEC EDGAR · CIK 1558569 · Services-Commercial Physical & Biological Research
More on ISPC
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results